Chemical inhibitors of Calpactin target various biochemical pathways and interactions to modulate the protein's function within cellular processes. Marimastat, as a matrix metalloproteinase inhibitor, can indirectly inhibit Calpactin by stabilizing the extracellular matrix. This stabilization limits the mechanical cues that otherwise lead to Calpactin's activation and subsequent cytoskeletal rearrangements. Bisindolylmaleimide I, a protein kinase C inhibitor, reduces the phosphorylation and activation of Calpactin, thereby influencing Calpactin's role in signaling cascades. Cytochalasin D disrupts actin polymerization and can inhibit Calpactin by blocking its association with the actin cytoskeleton, a critical step for Calpactin's involvement in cellular motility and structure maintenance. Paclitaxel, by hyperstabilizing microtubules, can also inhibit Calpactin by preventing the dynamic instability of microtubules required for Calpactin's function.
Further, ML-7 and Blebbistatin indirectly inhibit Calpactin by targeting myosin, a motor protein that works in concert with actin. ML-7 inhibits myosin light chain kinase, essential for actin-myosin interactions, while Blebbistatin inhibits myosin II ATPase activity, both leading to reduced Calpactin functionality in processes like cell contraction and motility. Rottlerin, as a PKC delta inhibitor, can decrease Calpactin's activity in cell adhesion and motility by impacting PKC delta-mediated signaling pathways. Y-27632 inhibits ROCK, thereby affecting Calpactin by preventing the downstream effects of Rho-associated protein kinase on the actin cytoskeleton. W-7, as a calmodulin antagonist, interferes with calcium signaling pathways, indirectly inhibiting Calpactin's function in cytoskeletal organization. Thapsigargin disrupts calcium homeostasis by inhibiting the SERCA pump, potentially inhibiting Calpactin's involvement in vesicle trafficking and membrane stabilization. Lastly, Jasplakinolide stabilizes actin filaments, inhibiting Calpactin by preventing necessary actin remodeling for its cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase inhibitor that can indirectly inhibit Calpactin by preventing the remodeling of the extracellular matrix, a process in which Calpactin is involved. By stabilizing the extracellular environment, Marimastat limits the mechanical cues that could lead to activation of Calpactin's role in cytoskeletal rearrangements. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a protein kinase C inhibitor. Calpactin is known to interact with PKC-regulated pathways, and by inhibiting PKC, Bisindolylmaleimide I can reduce the phosphorylation and subsequent activation of Calpactin involved in signaling cascades, leading to its functional inhibition. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin polymerization, which can inhibit Calpactin by preventing its association with the actin cytoskeleton, a crucial interaction for Calpactin's function in cellular processes such as motility and structure maintenance. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and can inhibit Calpactin by preventing the dynamic instability required for its function. Calpactin is implicated in linking the cytoskeleton components, and the hyperstabilization of microtubules could lead to a functional inhibition of Calpactin's role in this process. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), and by inhibiting MLCK, it can indirectly inhibit Calpactin by preventing the phosphorylation of myosin light chains. This phosphorylation is essential for actin-myosin interactions where Calpactin plays a regulatory role. Without proper myosin function, Calpactin's involvement in cytoskeletal rearrangement and cell motility is inhibited. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin is an inhibitor of myosin II ATPase activity. By inhibiting myosin II, Blebbistatin can indirectly inhibit Calpactin's role in actin-myosin-based processes such as cell contraction and motility, where Calpactin functions in tandem with myosin II. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $84.00 $166.00 $302.00 $2091.00 $5212.00 $16657.00 | 51 | |
Rottlerin is known as a selective PKC delta inhibitor. Since PKC delta is implicated in signal transduction pathways that involve Calpactin, inhibiting PKC delta with Rottlerin can decrease the functional activity of Calpactin within these pathways, particularly in processes related to cell adhesion and motility. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, which can indirectly inhibit Calpactin by preventing the downstream effects of Rho-associated protein kinase on the actin cytoskeleton, where Calpactin is active. This disruption can lead to reduced cytoskeletal reorganization and cell motility, processes in which Calpactin is involved. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 is a calmodulin antagonist that can inhibit Calpactin by interfering with calcium signaling pathways. Since Calpactin is sensitive to calcium levels due to its role in cytoskeletal organization and cell signaling, antagonizing calmodulin activity with W-7 can indirectly inhibit the functional activity of Calpactin. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels. Elevated calcium can disrupt numerous signaling pathways, including those involving Calpactin, potentially inhibiting its function in cellular processes such as vesicle trafficking and membrane stabilization. | ||||||